Form 4: Cingulate Inc. Executive Matthew Brams Acquires Stock Options

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, was granted 1,000 stock options on December 31, 2024.

Summary

• Matthew Brams, the EVP and Chief Medical Officer of Cingulate Inc., acquired 1,000 stock options on December 31, 2024.
• The options have an exercise price of $4.93 per share.
• These options were granted as part of Mr. Brams' employment agreement.
• The options are exercisable starting December 31, 2024, and expire on December 31, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options to a key executive like the Chief Medical Officer can be seen as a positive incentive aligning his interests with the company's success.
• The long expiration period of the options, until 2034, suggests a long-term commitment from the executive.

Risks

• There are no immediate risks associated with this transaction.
• The value of the options is dependent on the future performance of Cingulate Inc.'s stock price.

Future Outlook

This document does not contain any forward-looking statements or guidance.

Management Comments

• The option was granted pursuant to the terms of Mr. Bram's Employment Agreement, as amended.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, although specific terms can vary widely between companies.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the executive's performance leads to an increase in the company's stock price.
• The grant incentivizes the executive to work towards the company's long-term success.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cingulate Inc., Matthew Brams, EVP, Chief Medical Officer